28A-1110225
Patent pending
Oligodendrocytes are glial cells located in the central nervous system (CNS) and play a key role in the transmission of nerve signals and the neuroprotection by myelinated neurons. Dysfunction or loss of oligodendrocytes lead to demyelinating diseases, such as multiple sclerosis (MS). In terms of treatment, the promotion of remyelination at the site of myelin injury is the main problem that needs to be resolved.
The small-molecule drug formulations (Y27632, SU9516, and forskolin) significantly promoted remyelination in the central nervous system in a murine model of cuprizone-induced demyelination. These results may contribute to the treatment of demyelinating diseases and the development of regenerative medicine.
- This is the first study to identify a combinatorial drug formulation to promote oligodendrocyte-like cells from a cell reprogramming study
- Provide a possible cell-free therapy for treating demyelination disease by small molecules cocktail
- Small molecule drug formulations for the treatment of clinical neurodegenerative diseases
- Small molecule drug formulations are used in the development of health food related to neurodegeneration
Jean Lu, Hsiao-Chun Huang, Ming-Hsi Chuang
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Methods of treating demyelinating diseases